Acetaminophen
1. Pregnancy Evidence & Regulatory Labeling
FDA Pregnancy and Lactation Labeling Rule (PLLR 8.1) & EMA SmPC Section 4.6
Clinical Risk Summary
Acetaminophen is the first-line analgesic and antipyretic recommended by ACOG and SMFM during all trimesters of pregnancy when clinically indicated at the lowest effective dose. Extensive epidemiological data from prospective cohort studies involving hundreds of thousands of pregnancies have not demonstrated an increased risk of major congenital malformations, miscarriage, or stillbirth.
Human Pregnancy Experience & Clinical Studies
Multiple large-scale prospective cohort studies and meta-analyses (including Motherisk and European registries) demonstrate no causal association between therapeutic prenatal acetaminophen exposure and structural organ malformations or neurodevelopmental disorders.
Animal Reproductive & Developmental Toxicity Data
Reproductive studies in rats and mice at clinical human-equivalent doses revealed no evidence of teratogenicity or impaired fertility.
Clinical Considerations for Prescribers
Use at the lowest effective therapeutic dose (maximum 3,000 to 4,000 mg/24 hours maternal limit). Avoid combination products containing caffeine, phenylephrine, or decongestants unless specifically indicated.
Placental Transfer
Readily crosses the placenta via passive diffusion; fetal cord blood concentrations equilibrate with maternal plasma.
2. Lactation & Breastfeeding Safety
NIH / NLM LactMed® Database & FDA Labeling Section 8.2
Summary of Use during Lactation
Acetaminophen is considered compatible with breastfeeding by the American Academy of Pediatrics (AAP) and NIH LactMed. The amount excreted into human milk is small (Relative Infant Dose ~0.1% to 1.85% of the weight-adjusted maternal dose), far below pediatric therapeutic doses.
Drug Levels in Breast Milk & Relative Infant Dose
Peak breast milk concentrations occur 1 to 2 hours post-dose, with milk-to-plasma ratios ranging between 0.76 and 1.25.
Effects in Breastfed Infants & Monitored Signs
No adverse clinical reactions or hepatic effects reported in breastfed infants with standard maternal dosing; rare idiosyncratic maculopapular rash reported.
Effects on Lactation & Milk Production
No known adverse effect on maternal milk production or serum prolactin levels.
Alternate Medications with Established Lactation Data
3. Females & Males of Reproductive Potential
FDA Labeling Section 8.3 — Pregnancy Testing, Contraception & Infertility
Standard pre-treatment clinical assessment as indicated.
Review contraception duration based on drug elimination half-life.
No significant drug-induced impairment reported in standard models.
4. Regulatory Source Provenance & Comparison
Direct attribution to official regulatory documents without synthesized consensus
| Regulatory Organization | Jurisdiction | Document / Framework | Effective Date | Official Source Link |
|---|---|---|---|---|
|
National Institutes of Health (NIH) / NLM
LactMed® Database (Drugs and Lactation)
|
United States / Global | evidence_monograph | 2026-08-01 | Official Record |
|
European Medicines Agency (EMA)
EMA Summary of Product Characteristics (SmPC 4.6)
|
European Union | regulatory_label | Recent | Official Record |